Research programme: elsulfavirine fixed-dose combinations - Viriom

Drug Profile

Research programme: elsulfavirine fixed-dose combinations - Viriom

Latest Information Update: 28 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Viriom
  • Class Antivirals; Small molecules
  • Mechanism of Action Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical HIV infections

Most Recent Events

  • 24 Mar 2017 Preclinical trials in HIV infections in Russia (PO) (Viriom pipeline, March 2017)
  • 17 Mar 2017 Viriom intends to launch elsulfavirine fixed-dose combination in Russia in 2019
  • 17 Mar 2017 Viriom plans a clinical study of elsulfavirine fixed-dose combinations for HIV-infections in Russia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top